PPARγ Agonist Compounds for Blood-Brain Barrier Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PPARγ agonists face challenges in penetrating the blood-brain barrier (BBB) effectively, leading to low brain bioavailability and systemic dose-related side effects, limiting their efficacy in treating neurological disorders and other diseases.
Innovation Solution
Development of novel PPARγ agonist compounds with specific structural features, such as cyclic RA, RB, and RC groups, which enhance BBB permeability and reduce systemic exposure, allowing for targeted brain delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional PPARγ agonists are administered systemically, then therapeutic effects on diabetes and other diseases are achieved, but brain bioavailability remains low due to poor BBB penetration
Solution Approach 1:
The patent modifies the molecular structure of PPARγ agonists by introducing specific substituents at defined positions (e.g., R1-R6 groups in the core structure) to create compounds with enhanced BBB permeability while maintaining PPARγ activity. This localized structural modification allows the drug to achieve high brain concentrations without requiring high systemic doses.
Solution Approach 2:
The invention systematically varies chemical parameters including substituent types (halogen, alkyl, alkoxy, etc.), chain lengths, and molecular weight to optimize BBB penetration. By adjusting these molecular parameters, the patent achieves compounds that cross the BBB effectively while maintaining adequate PPARγ agonist activity.
2Quantity of substance
If high systemic doses of PPARγ agonists are used to achieve therapeutic brain concentrations, then neurological effects may be achieved, but intolerable side effects occur
Solution Approach 1:
The patent designs compounds with specific structural features (e.g., particular substituent patterns at R1-R6 positions) that selectively enhance BBB penetration while maintaining appropriate systemic exposure. This localized molecular optimization allows the drug to concentrate in the brain without requiring high systemic doses that cause side effects.
Solution Approach 2:
The modified PPARγ agonist compounds act as intermediaries that facilitate selective drug delivery to the brain. By incorporating specific molecular features, these compounds mediate selective transport across the BBB while limiting systemic distribution, thereby achieving brain therapeutic concentrations without intolerable side effects.
3Quantity of substance
If conventional PPARγ agonists are used, then PPARγ activation and klotho protein increase occur, but the therapeutic efficacy for neurological disorders is limited due to low brain bioavailability
Solution Approach 1:
The patent introduces specific substituent patterns (e.g., halogen, alkyl, alkoxy groups at defined positions) that locally enhance BBB penetration capability while preserving PPARγ activation. This localized structural optimization enables the compound to achieve high brain concentrations, thereby improving therapeutic efficacy for neurological disorders.
Solution Approach 2:
The invention systematically optimizes molecular parameters including substituent identity, chain length, and molecular weight to maximize brain delivery. By adjusting these parameters, the patent achieves compounds that simultaneously maintain PPARγ activity and achieve sufficient brain concentrations for effective neurological treatment.
Data Source
AI summary
The present invention provides compounds as PPAR agonists and their application, involving a new class of peroxisome proliferator-activated receptor (PPAR) gamma receptor agonist, which can inhibit the production of mitochondrial reactive oxygen species, and most of which can readily cross the blood-brain barrier. The present invention also includes pharmaceutical uses of the compounds.